Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019158 (
hepatitis
)
30,205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The relationship between hepatitis C virus RNA and hepatitis C virus-associated antibodies (antibody against the putative capsid protein and C-100 antibody) was determined by nested polymerase chain reaction and enzyme-linked immunosorbent assay in serial serum samples obtained from eight chimpanzees experimentally infected with hepatitis C virus. Three different patterns emerged from the polymerase chain reaction data: the first (group 1) was acute resolving
hepatitis
with transient appearance of HCV RNA (two cases). The second (group 2) had chronic hepatitis with persistent hepatitis C virus RNA positivity (four cases) and the third (group 3) had chronic hepatitis with intermittent appearance of hepatitis C virus RNA (two cases). In four of eight animals, hepatitis C virus RNA was first detectable in serum 1 wk after inoculation. Although serum HCV RNA was detected in all infected chimpanzees, two were positive only for antibody against the putative capsid protein, whereas two were positive only for antibody to C-100 antigen. In four of eight cases, antibody against the putative capsid protein appeared earlier than did antibody to C-100 antigen, was detected just before or coincident with rising glutamate pyruvate transaminase values and remained positive for a long time even after recovery. Six of eight animals (75%) were still hepatitis C virus RNA positive 1 yr after inoculation, suggesting that the risk of development of the chronic carrier state is high in hepatitis C
virus infection
. Furthermore, there did not appear to be a good correlation between antibody titer in serum and hepatitis C virus infectivity titer.
...
PMID:Three different patterns of hepatitis C virus infection in chimpanzees. 131 87
Clinical, animal, and epidemiologic evidence indicates that exogenous steroids influence the risk of hepatocellular carcinoma (HCC) and a recent study suggested that parity also may increase the risk of this tumor in women. The latter hypothesis was evaluated in the data from a case-control study which was carried out in Athens and covered 166 male and 19 female cases of HCC, and 381 male and 51 female hospital controls. Among males, there was no association between the number of liveborn children and risk of HCC, whereas among women, there was a suggestive positive association. Compared with women with one or two children, the relative risk for HCC was 0.6 among nulliparous women, 1.3 among those with three or four children and 1.7 among those with five or more children. The association of parity with risk of HCC was limited to women who were positive for
hepatitis
-B surface antigen (HBsAg) and was not confounded by
hepatitis
-C
virus infection
or tobacco smoking. The small number of HCC cases does not permit firm conclusions. If confirmed, however, these results would provide the foundation for a practical preventive advice that could be given to women who are positive for HBsAg.
...
PMID:Liveborn children and risk of hepatocellular carcinoma. 131 8
A cDNA encoding the spike (S) protein of the neurovirulent murine coronavirus JHMV variant cl-2 was isolated and sequenced. Analysis of the cDNA revealed that the S protein consists of 1376 amino acids, as does the S protein of mouse
hepatitis
virus 4. We inserted the cDNA into the genome of vaccinia virus to obtain a recombinant vaccinia virus (rVV). The S protein expressed in RK13 cells infected by the rVV was shown to be electrophoretically and immunologically indistinguishable from the S protein produced in DBT cells infected with cl-2 virus. RVV infection of rats and mice induced S protein-specific antibody production detectable by immunofluorescence and neutralization. Moreover, the S protein expressed by the rVV induced syncytium formation not only in mouse DBT and L cells, which are susceptible to cl-2
virus infection
, but also in rabbit RK13 cells, which are not susceptible to cl-2
virus infection
. This result suggests the possibility that RK13 cells have binding sites for the cl-2 virus S protein.
...
PMID:Molecular cloning and expression of a spike protein of neurovirulent murine coronavirus JHMV variant cl-2. 131 38
Sera from 103 patients were tested for hepatitis C virus RNA by nested polymerase chain reaction assay. Using primers from the highly conserved 5'-untranslated region, we detected hepatitis C virus RNA in 67 (88.2%) of 76 patients positive for antibody to hepatitis C virus by both second-generation and neutralization enzyme immunoassays. Hepatitis C virus RNA was detected in 93% of patients who had been infected for 10 yr or less and in 89% of those who had been infected for longer than 10 yr. Hepatitis C virus RNA was detected in all patients with chronic hepatitis, active cirrhosis or hepatocellular carcinoma and in 50% of those with nonspecific reactive
hepatitis
or inactive cirrhosis. Hepatitis C virus RNA was not detected in sera from 22 patients negative for antibody to hepatitis C virus or in 5 patients positive for antibody to hepatitis C virus by second-generation but not by neutralization enzyme immunoassay. Using primers from the less conserved nonstructural region 4, we detected hepatitis C virus RNA at a lower frequency, in 66% of patients who were positive for antibody to hepatitis C virus by both second-generation and neutralization enzyme immunoassays. The detection rate was higher in patients with frequent parenteral exposure. Our study showed that hepatitis C viremia can be detected in most patients with hepatitis C
virus infection
, including those with long-standing infection or advanced liver disease.
...
PMID:Hepatitis C viremia in patients with hepatitis C virus infection. 131 37
We reanalyzed the results of a pilot study of recombinant alpha-interferon therapy for chronic non-A, non-B
hepatitis
in light of the recent discovery of the hepatitis C virus and the development of diagnostic assays for this agent. Stored serum samples from 10 patients treated between 1984 and 1986 were tested for antibody to hepatitis C virus and hepatitis C virus RNA before, during and after therapy. In addition, the current clinical, serum biochemical and virological statuses of these patients were evaluated to determine the long-term effects of interferon therapy. All patients had evidence of hepatitis C
virus infection
, with hepatitis C viral RNA, antibody to hepatitis C virus or both markers detectable in serum. Serum hepatitis C virus RNA was found to disappear in seven of eight patients whose aminotransferase levels became normal with interferon therapy but remained present in two patients who did not respond to therapy. Levels of hepatitis C virus RNA decreased and disappeared when serum aminotransferases fell to normal levels but rose with subsequent elevation of aminotransferase levels in two patients who had relapses in disease when interferon was stopped. During a follow-up of 3 to 6 yr, hepatitis C virus RNA remained undetectable in the six patients whose serum aminotransferase levels remained normal after interferon therapy. However, neither initial titers of hepatitis C virus RNA nor disappearance of viral RNA from serum during treatment predicted a sustained response. Thus long-term beneficial responses to alpha-interferon can occur in patients with chronic hepatitis C and are associated with sustained loss of hepatitis C virus RNA from serum.
...
PMID:Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. 131 38
Our purpose was to ascertain whether alcohol abuse is a risk factor for the development of hepatocellular carcinoma in urban southern Africa blacks and, if so, to relate alcohol consumption to other possible risk factors such as persistent
hepatitis
-B-
virus infection
, smoking, male sex, in this subpopulation. A prospective, hospital-based, case-control format involving 101 patients with hepatocellular carcinoma and 101 controls was used. The mean age of the patients was 53.7 +/- 1.85 years and the male:female ratio 3.2:1. An increased risk was found, but only in urban men over the age of 40 years who habitually drank more than 80 g of ethanol daily. The risk remained after adjusting for chronic hepatitis-B infection, smoking, and sex (odds ratio 4.4, 95% confidence interval 1.3 to 16.6; p = 0.003). Smoking proved not to be a risk factor, either alone or in concert with alcohol consumption.
Hepatitis
-B infection was confirmed as a major risk in younger men and in women, but in urban men over the age of 40 years alcohol abuse was a greater risk. Current
hepatitis
-B infection and alcohol abuse were additive risks.
...
PMID:Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. 131 67
In 1987 Chiron Co. in USA and Arima et al. in Japan reported successful isolation of clones coding peptides specific for non-A, non-B
hepatitis
infection. Hepatitis C virus (HCV) genome reported by the Chiron is supposed to have structural proteins of core, matrix, envelope and non-structural proteins of NS 1-5 from 5' to 3' end. C-100 antibody of which antigen is derived from the NS 3-4 region of the HCV genome is used generally, it is not sufficient to diagnose hepatitis C. On the other hand, the nucleotide and amino acid sequences in the epitope of N-14 clone established by Arima et al. have homology to those of core region of the HCV genome. Usually there are some mutation in sequences of HCV genome, but there is little mutation in 5' non-coding region and core protein area. Therefore we could diagnose hepatitis C more exactly by using N-14 antibody. In the present study N-14 antibody was determined in 871 healthy subjects and 285 cases with liver diseases by an ELISA. 1.6% of healthy subjects and 70-75% of cases with non-A, non-B chronic liver diseases are positive for N-14 antibody. In acute non-A, non-B
hepatitis
, 33.3% of sporadic cases and 75.0% of post-transfusion cases are positive for the test. As only 2 of 100 cases with other liver diseases are positive for the test, the N-14 antibody test seems to be highly sensitive and specific for the non-A, non-B
hepatitis
virus infection
. These 1156 cases were tested for the C-100 antibody as well. No much difference between the results by using these tests, 15-20% of discrepancy between the tests, has been observed. In conclusion hepatitis C can be diagnosed exactly by using N-14 antibody as well as by C-100 antibody. In addition for more exact diagnosis of hepatitis C, tests by N-14 antibody in combination with C-100 antibody will be prefered to determine anti HCV.
...
PMID:[Clinical significance of N-14 antibody (ELISA) in diagnosis of non-A, non-B liver disease]. 131 60
We reviewed the records of all patients with a diagnosis of malignancy who were treated at our center and who had not had chemotherapy for at least 18 months, to assess the prevalence of chronic hepatitis B surface antigen (HBsAg)-negative
hepatitis
, to assess the prevalence of a marker of hepatitis C
virus infection
, and to determine the severity of chronic liver disease. Of 557 eligible patients, 38 (6.8%) had chronic HBsAg-negative
hepatitis
. Of these 38 patients, 20 (52.6%) had a marker of hepatitis C
virus infection
. The prevalence of chronic HBsAg-negative
hepatitis
was higher in patients previously treated for leukemia than in patients treated for another malignancy (11.8% vs 4.6%; p = 0.004). The liver biopsy revealed chronic active hepatitis or cirrhosis or both in 8 (28%) of 28 patients with clinical chronic HBsAg-negative
hepatitis
. Four patients without hepatitis C
virus infection
who underwent liver biopsy had hepatitis B virus antigen in the liver, confirmed by immunohistochemistry studies. One patient uninfected with hepatitis C virus had hemochromatosis. We conclude that infection with hepatitis C virus was the major cause of chronic HBsAg-negative
hepatitis
in pediatric patients previously treated for malignancy; the cause remained unidentified in 30% of the patients.
...
PMID:Chronic hepatitis B surface antigen-negative hepatitis after treatment of malignancy. 132 Jun 73
Between January 1987 and April 1988 following 462 open heart surgery operations, 83 patients with icteric
hepatitis
were seen. Among them 59 patients were anti-HCV positive with the Ortho anti-HCV test, these findings suggested a hepatitis C
virus infection
. The source of
viral infection
was searched, and a prothrombin complex concentrate which had been used during that period, seemed to be the potential cause of bloodborne hepatitis C. The results suggest that special care is required when using such blood products.
...
PMID:[The role of HCV in the pathogenesis of post-transfusion hepatitis]. 132 95
The prevalence of
hepatitis
virus markers in patients with chronic liver diseases from two countries has been studied: 68 patients (38 alcoholic hepatitis or cirrhosis, 30 chronic HBsAg-positive
hepatitis
) from Hungary as well as 109 patients (55 alcoholic liver disease, 45 chronic hepatitis or cryptogenic cirrhosis and 9 hepatoma) from Romania were examined for HBsAg, anti-HBs, anti-HBc, anti-HCV and anti-HDV, using the corresponding Abbott Elisa test systems. In alcoholic liver disease HBsAg occurred in 6/38 patients from Hungary and in 22/55 patients respectively, that is HBV markers occurred with significantly higher frequency in alcoholic patients from Romania (p less than 0.05). In the Hungarian group a total of 36 patients were HBsAg positive and out of them 5 had anti-HDV (13.9%), while out of 21 Romania HBsAg carriers 10 patients had anti-HDV (47.6%). Among 9 hepatoma patients 4 had HBsAg, 6 anti-HBs and 7 anti-HBc and 4 had anti-HCV and 3 had anti-HDV. One patient with hepatoma had both HBsAg and anti-HCV plus anti-HDV as well. Results suggest that the infection with
hepatitis
viruses in alcoholic liver diseases is more common in Romania than in Hungary, and the prevalence of delta
virus infection
in HBV carriers is also significantly higher in Romania than in Hungary.
...
PMID:[Hepatitis virus (HBV, HCV, HDV) markers in chronic liver diseases. Comparative studies in two East-Central European countries]. 132 99
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>